ライフサイエンスコーパス: dengue virus

1 ts (PRNTs) were performed to detect ZIKV and dengue virus.

2 ridae family including hepatitis C virus and dengue virus.

3 seroneutralisation assays for Zika virus and dengue virus.

4 e and, most abundantly, in the RNA genome of dengue virus.

5 ely infected by ZIKV, but not by the related dengue virus.

6 tion neutralisation assay for Zika virus and dengue virus.

7 n and conserved across the four serotypes of dengue virus.

8 n of robust correlates of protection against dengue virus.

9 esponses seen in humans naturally exposed to dengue virus.

10 nged with Enterobacter cloacae, Sindbis, and Dengue viruses.

11 reduction neutralisation assays for Zika and dengue viruses.

12 For dengue viruses 1 to 4 (DENV1-4), a specific range of ant

13 To find critical conserved amino acids in dengue viruses, 120 complete genomes of each serotype we

14 l inoculation of embryonic mouse brains with dengue virus 2 (DENV2), and found that DENV2 is sufficie

15 a soluble variant of the E protein (E85) of dengue virus 2 (DENV2).

16 Nile virus, Japanese encephalitis virus, and dengue virus 2.

17 IMPORTANCE Dengue virus, a member of the family Flaviviridae, can r

18 We recently developed Alexa Fluor-labeled dengue viruses (AF DENVs) to characterize antigen-specif

19 Dengue virus affects hundreds of millions of people each

20 1 activity for proviral lipophagy.IMPORTANCE Dengue virus alters host cell lipid metabolism to promot

21 Dengue virus, an approximately 10.7-kb positive-sense RN

22 lex between the full-length NS5 protein from dengue virus, an octameric cap-0 viral RNA substrate bea

23 Because of the similarity of Zika and dengue viruses, an analogous unwanted outcome might occu

24 us, varicella zoster virus, cytomegalovirus, dengue virus and chikungunya virus), bacterial (for exam

25 ding infections with two common arboviruses, dengue virus and chikungunya virus.

26 provide a path to a subunit vaccine against dengue virus and have implications for the design and mo

27 thin the Flaviviridae family, exemplified by dengue virus and hepatitis C virus.

28 ible to ZIKV compared to the closely related dengue virus and induced the expression of alpha interfe

29 es are the limited assessment of the role of dengue virus and other possible cofactors, the small num

30 The dengue virus and related flaviviruses are an increasing

31 provide protection against all serotypes of dengue virus and will be economical and uncomplicated in

32 ed by Ae. aegypti include the 2 flaviviruses dengue virus and yellow fever virus and the alphavirus c

33 flaviviruses and neutralize a broad range of dengue virus and ZIKV isolates.

34 ses of global health significance, including dengue viruses and chikungunya virus.

35 proteostasis of influenza as well as HIV and dengue viruses and led to inhibition of viral growth and

36 of weak but crucial binding between the DV (dengue virus) and its CLEC5A receptor.

37 trol of mosquito-borne diseases (malaria and dengue virus), and antibiotic elimination of infectious

38 the family Flaviviridae(yellow fever virus, dengue virus, and bovine viral diarrhea virus) and a hum

39 assays were performed for detection of ZIKV, dengue virus, and chikungunya virus; IgM enzyme-linked i

40 nfluenza virus, respiratory syncytial virus, dengue virus, and Ebola virus, among others.

41 eurotropic viruses, such as HSV, Zika virus, dengue virus, and rabies virus.

42 aly, potential interactions between ZIKV and dengue virus, and the prospects for the development of a

43 ses, such as Zika virus, yellow fever virus, dengue virus, and West Nile virus (WNV), are a serious c

44 rculating, such as HIV-1, Hepatitis C virus, Dengue virus, and West Nile virus.

45 Reports suggest that anti-dengue virus antibody may enhance Zika virus replication

46 Among the 4 serotypes of dengue virus, antibody-dependent enhancement is thought

47 vaccination.IMPORTANCE The four serotypes of dengue virus are the causative agents of dengue fever an

48 lular and functional properties of the acute dengue virus B cell response and its role in protection

49 rus, lymphocytic choriomeningitis virus, and dengue virus but not for the nonenveloped poliovirus.

50 Finally, capsid protein of Dengue virus, but not West Nile virus, induced ribosomal

51 specific detection of Zika, chikungunya, and dengue viruses by coupling reverse-transcription loop-me

52 ribe available data and discuss new ideas on dengue virus capsid functions and interactions.

53 alent vaccine candidate based on recombinant dengue virus capsid proteins, efficiently produced in Es

54 The non-structural 1 (NS1) protein of the dengue virus circulates in infected patients' blood samp

55 f children with suspected ZIKV infection for dengue virus coinfection should be considered in dengue-

56 Dengue is an acute febrile illness caused by dengue virus (DENV) and a major cause of morbidity and m

57 Dengue virus (DENV) and chikungunya virus (CHIKV) are im

58 gue disease despite the global prevalence of dengue virus (DENV) and its mosquito vectors.

59 Dengue virus (DENV) and its primary mosquito vectors Aed

60 The presence of dengue virus (DENV) and Japanese encephalitis virus NS1s

61 pping geographical distribution of ZIKV with dengue virus (DENV) and other flaviviruses, possibly res

62 the world where other flaviviruses, such as dengue virus (DENV) and West Nile virus (WNV), are endem

63 vaccines for pathogenic flaviviruses such as dengue virus (DENV) and Zika virus.

64 Anti-Dengue virus (DENV) antibodies can be either protective

65 Although dengue virus (DENV) antibodies can neutralize or enhance

66 Zika virus (ZIKV) and dengue virus (DENV) are antigenically related flavivirus

67 West Nile virus (WNV) and Dengue virus (DENV) are important human pathogens for wh

68 pearance was not observable with a different dengue virus (DENV) as our control.

69 to investigate transfusion-transmitted (TT) dengue virus (DENV) by DENV RNA-positive donations.

70 Dengue virus (DENV) causes 400 million infections annual

71 Dengue virus (DENV) causes several hundred million human

72 virus (ZIKV), chikungunya virus (CHIKV), and dengue virus (DENV) cocirculate in Nicaragua.

73 The related flavivirus dengue virus (DENV) cocirculates in many JEV-endemic are

74 emerging virus that has recently spread into dengue virus (DENV) endemic regions and cross-reactive a

75 he last few decades, the global incidence of dengue virus (DENV) has increased dramatically, and it i

76 Anti-dengue virus (DENV) immunoglobulin M (IgM) seroconversio

77 (DEP) chip was conducted to rapidly detect a dengue virus (DENV) in vitro based on the fluorescence i

78 inuing studies of vaccine approaches against dengue virus (DENV) infection are warranted, particularl

79 Dengue virus (DENV) infection in the presence of reactiv

80 results in areas with various levels of past dengue virus (DENV) infection incidence.

81 Antibody-dependent enhancement (ADE) of dengue virus (DENV) infection is believed to contribute

82 Dengue virus (DENV) infection is considered a major publ

83 A method for the rapid diagnosis of early dengue virus (DENV) infection is highly needed.

84 Dengue virus (DENV) infection is the most common mosquit

85 Dengue virus (DENV) infection results in the production

86 and functional properties in the context of dengue virus (DENV) infection.

87 We sought to characterize dengue virus (DENV) infections among febrile children en

88 Three-quarters of the estimated 390 million dengue virus (DENV) infections each year are clinically

89 The global spread of dengue virus (DENV) infections has increased viral genet

90 The clinical severity of secondary dengue virus (DENV) infections is associated with antibo

91 approaches to differentially detect ZIKV and dengue virus (DENV) infections, accentuating the urgent

92 G avidity against both Zika virus (ZIKV) and dengue virus (DENV) infections.

93 Each year dengue virus (DENV) infects 400 million human but causes

94 The mosquito-transmitted dengue virus (DENV) infects millions of people in tropic

95 Dengue virus (DENV) infects ~400 million people annually

96 Dengue virus (DENV) is a close family member of ZIKV and

97 Dengue virus (DENV) is a major public health threat worl

98 Dengue virus (DENV) is a member of the genus Flavivirus

99 Dengue virus (DENV) is a mosquito-borne Flavivirus class

100 Dengue virus (DENV) is a mosquito-borne flavivirus that

101 Dengue virus (DENV) is a mosquito-transmitted RNA virus

102 ding of the correlates of protection against dengue virus (DENV) is poor and hinders the development

103 Dengue virus (DENV) is responsible for growing numbers o

104 Dengue virus (DENV) is the causative agent of dengue fev

105 Dengue virus (DENV) is the most significant human arbovi

106 Exposure to dengue virus (DENV) is thought to elicit lifelong immuni

107 so required for the post-entry stages of the dengue virus (DENV) life cycle.

108 iagnostic performance of an RDT that detects dengue virus (DENV) nonstructural protein 1 (NS1) and an

109 The mechanism of ZIKV NS5 resembles dengue virus (DENV) NS5 and not its closer relative, Spo

110 ian cells, ZIKV, but not the closely related dengue virus (DENV) or West Nile virus (WNV), can effici

111 Robust dengue virus (DENV) replication requires lipophagy, a se

112 Transmission of dengue virus (DENV) requires successful completion of th

113 A deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain l

114 Efficacy varied by dengue virus (DENV) serotype and prevaccination dengue i

115 public health problem and is caused by four dengue virus (DENV) serotypes (DENV1-4).

116 Zika virus (ZIKV) and the 4 dengue virus (DENV) serotypes are mosquito-borne Flavivi

117 The four dengue virus (DENV) serotypes are mosquito-borne flavivi

118 All 4 dengue virus (DENV) serotypes are now simultaneously cir

119 The four dengue virus (DENV) serotypes, DENV1 through 4, are ende

120 the critical question of whether preexisting dengue virus (DENV) T cell immunity modulates these resp

121 The skin is the site of dengue virus (DENV) transmission following the bite of a

122 Our findings suggest that Dengue virus (DENV) transmission is limited by low winte

123 d on 141 viremic dengue patients, have lower dengue virus (DENV) transmission potential and have a lo

124 arily has been proposed as a tool to control dengue virus (DENV) transmission; however, evidence sugg

125 d for detection of consensus DNA sequence of Dengue virus (DENV) using methylene blue (MB) as an inte

126 eterminants of small plaque phenotype in two dengue virus (DENV) vaccine candidates, DENV-3 PGMK30FRh

127 The cross-reactivity of ZIKV epitopes to dengue virus (DENV) was tested using IFN-gamma-ELISPOT a

128 has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIK

129 Dengue virus (DENV), a member of the Flaviviridae family

130 athogens including yellow fever virus (YFV), dengue virus (DENV), and Zika virus (ZKV), all of which

131 Four serotypes of mosquito-borne dengue virus (DENV), evolved from a common ancestor, are

132 a mosquito-borne flavivirus with homology to Dengue virus (DENV), has become a public health emergenc

133 istence of ZIKV, but not the closely related dengue virus (DENV), in the testis and epididymis of mal

134 compared with other flaviviruses, including dengue virus (DENV), resulting in immunological cross-re

135 antibodies that cross-react with the related dengue virus (DENV), we designed modified prM-E RNA enco

136 rgence and spread of flaviviruses, including dengue virus (DENV), West Nile virus (WNV), and Zika vir

137 strategies to treat DENV disease.IMPORTANCE Dengue virus (DENV), which causes febrile illness, is tr

138 une responses protect against infection with dengue virus (DENV), yet cross-reactivity with distinct

139 Recently, a novel luciferase-ZIKV- and -dengue virus (DENV)-based serological assay, which consi

140 ic tests, particularly for pregnant women in dengue virus (DENV)-endemic regions.

141 The mechanism by which some dengue virus (DENV)-infected individuals progress to sev

142 low-density lipoprotein (VLDL) discriminated dengue virus (DENV)-infected subjects from ND subjects,

143 While it is widely accepted that dengue virus (DENV)-neutralizing antibody (nAb) titers a

144 e show that expression of ZIKV-NS2A, but not Dengue virus (DENV)-NS2A, leads to reduced proliferation

145 Although some cross-reactive dengue virus (DENV)-specific antibodies can enhance ZIKV

146 Maternal-fetal transferred dengue virus (DENV)-specific antibodies have been implic

147 infections-including the related flavivirus, dengue virus (DENV)-the transmission of ZIKV is anticipa

148 ltra-sensitive, and rapid detection of whole dengue virus (DENV).

149 ly during infection by an RNA virus, namely, dengue virus (DENV).

150 posed to Asian ZIKV(C), African ZIKV(M), and dengue virus (DENV).

151 yribonucleic acid (DNA) detection related to dengue virus (DENV).

152 ated individuals to infection by the related Dengue virus (DENV).

153 rotective immunity against pathogens such as dengue virus (DENV).

154 ZIKV viral RNA replication when compared to dengue virus (DENV).

155 is study defined the genetic epidemiology of dengue viruses (DENV) in two pivotal phase III trials of

156 Dengue viruses (DENV) infect 50 to 100 million people ea

157 s that pose global health threats, including dengue viruses (DENV), yellow fever virus (YFV), and Zik

158 Dengue viruses (DENV-1-4) pose a transfusion-transmissio

159 by four antigenically distinct serotypes of dengue virus (DENV1-4), and although serotype-specific a

160 Dengue viruses (DENVs) are mosquito-borne flaviviruses t

161 travalent DLAV vaccine (TV005) with pools of dengue virus-derived predicted major histocompatibility

162 lectrochemical DNA hybridization sensors for Dengue virus detection, spanning both labeled and label-

163 OCK), to detect specific strains of Zika and Dengue virus, distinguish pathogenic bacteria, genotype

164 responding proteins from the closely related dengue virus do not have the same effect on neurogenesis

165 eting the fusion loop of the glycoprotein of dengue virus dominated the antibody response, two smalle

166 sulfate proteoglycans that are receptors for dengue virus during infection of Vero cells and hepatocy

167 Here we found that the NS3 protein of dengue virus (DV) bound to 14-3-3varepsilon and prevente

168 protects evenly against the four circulating Dengue virus (DV) serotypes remains elusive.

169 opt a protein fold remarkably similar to the dengue virus E glycoprotein and related class II viral f

170 didate that contains truncated, recombinant, Dengue virus envelope protein from all four Dengue virus

171 d functional homologies between the Zika and Dengue viruses' envelope proteins raise the possibility

172 sin (OAS), given that the patients had prior dengue virus exposures.

173 ordering effect of influenza virus, HIV, and Dengue virus FPs has been consistently observed.

174 ed sequences present in all the serotypes of Dengue virus has been employed for fabrication of a geno

175 Dengue virus has been shown to be particularly sensitive

176 Dengue virus has emerged as an important arboviral infec

177 ntibody to correlate with protection against dengue virus have highlighted the need for a human DENV

178 ctivation was observed during infection with dengue virus, hepatitis C virus and influenza virus.

179 Past dengue virus history did not differ significantly betwee

180 Recent efforts to rescreen dengue virus human antibodies for ZIKV cross-neutralizat

181 s provide evidence of OAS in the acute-phase dengue virus immune response, providing a basis for futu

182 What was once blurred and confused with dengue virus in both diagnosis and name has since become

183 small molecules reflected the replication of dengue virus in different tissues and the extent of tiss

184 capabilities of Zika virus-immune serum for dengue virus in vitro.

185 Asymptomatic dengue virus-infected individuals are thought to play a

186 profile in monocytes isolated from ZIKV- and dengue virus-infected patients was comparable, except fo

187 plasma collected from patients suspected of dengue virus infection (n = 220) and individuals not sus

188 n (n = 220) and individuals not suspected of dengue virus infection (n = 45) were tested by the RT-ii

189 Wolbachia infection of mosquitoes can block dengue virus infection and is tested in field trials, bu

190 All patients tested were negative for dengue virus infection as assessed by RT-PCR.

191 suggest that India has the largest number of dengue virus infection cases worldwide.

192 Given that dengue virus infection elicits such a broad range of cli

193 Dengue virus infection has become a global concern, and

194 CYD-TDV dengue vaccine against asymptomatic dengue virus infection has not been previously assessed.

195 e aimed to assess the role of Zika virus and dengue virus infection in developing Guillain-Barre synd

196 s, serology may be used for the detection of dengue virus infection in the acute phase.

197 The annual incidence of asymptomatic dengue virus infection in this age group was 14.8%, whic

198 hat can provide long-term protection against dengue virus infection is needed.

199 of effective vaccination strategies against dengue virus infection is of high global public health i

200 In this study, we observed the effects of dengue virus infection on the profile of small molecules

201 otective immune correlates following natural dengue virus infection remain undefined, which makes it

202 Dengue virus infection typically causes mild dengue feve

203 Despite the clear medical importance of dengue virus infection, the mechanism of viral replicati

204 nd one sample each was confirmed for ZIKV or dengue virus infection.

205 NCE: Antibodies can protect from symptomatic dengue virus infection.

206 world's population is exposed to the risk of dengue virus infection.

207 readily detectable and comparable to natural dengue virus infection.

208 derstanding of the innate immune response to dengue virus infection.

209 body titers in cases were unrelated to prior dengue virus infection.

210 tions such as tuberculosis, melioidosis, and dengue virus infection.

211 s for achieving long-term protection against dengue virus infection.IMPORTANCE Continuing studies of

212 re were a total of 58.40 million symptomatic dengue virus infections (95% uncertainty interval [95% U

213 served vaccine efficacy against asymptomatic dengue virus infections is expected to translate into re

214 Unreported and unrecognised apparent dengue virus infections make it difficult to estimate th

215 Secondary dengue virus infections were also shown to influence dis

216 ction and immunopathogenesis associated with dengue virus infections, a reliable correlate of protect

217 virus antibodies have the ability to enhance dengue virus infections, which is important, because in

218 tegies, which are urgently needed to control dengue virus infections.

219 Dengue virus is a mosquito-borne pathogen that causes up

220 Dengue virus is an arthropod-borne virus transmitted pri

221 A as well as specific nucleotides.IMPORTANCE Dengue virus is an important human pathogen responsible

222 Dengue virus is an increasingly global pathogen.

223 ika virus has emerged in the Americas, where dengue virus is endemic.

224 , because in many Zika virus-affected areas, dengue virus is expected to remain endemic.

225 Although a vaccine for dengue virus is now available in a few countries, its re

226 The process of RNA replication by dengue virus is still not completely understood despite

227 the search for an efficient vaccine against dengue virus is the immunodominance of the fusion loop e

228 Dengue virus is the most important mosquito-borne pathog

229 evelopment of dengue therapeutics.IMPORTANCE Dengue virus is the most widespread arbovirus, causing a

230 cribed a multiplex NAAT for the detection of dengue virus, Leptospira, and Plasmodium species with a

231 utics that target this essential step of the dengue virus life cycle.

232 he interferon-mediated antiviral response to dengue virus may aid in the development of novel therape

233 Our studies demonstrate a region on dengue virus necessary for 5J7 binding and neutralizatio

234 s, revealed that LNPs induced high titers of Dengue virus neutralizing antibodies, with or without co

235 d Bartonella), and 13 viruses (parechovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps

236 Dengue virus nonstructural protein 4B (NS4B) is a membra

237 The approach is demonstrated with the dengue virus NS2B-NS3 protease in complex with a high-af

238 g of 8 of the 13 substrate cleavage sites by dengue virus NS2B/NS3 protease.

239 Dengue virus NS5 also binds SLAs from different serotype

240 We show that dengue virus NS5 binds SLA with a 1:1 stoichiometry and

241 recently discovered allosteric pocket on the dengue virus NS5 polymerase.

242 Quantitatively characterizing dengue virus NS5-SLA interactions will facilitate the de

243 ations previously exposed to any of the four dengue viruses or West Nile virus, or vaccinated against

244 logous epitope located at the surface of the dengue virus particle.

245 into the underlying molecular mechanisms of dengue virus pathogenesis, and could help to discriminat

246 understanding of the impact of antibodies in dengue virus pathogenesis.

247 interferon (IFN-gamma) when stimulated with dengue virus peptide pools.

248 ive analysis of the interactions between the dengue virus polymerase NS5 and SLA in solution has not

249 against the prevalent flavivirus.IMPORTANCE Dengue virus poses one of the most serious public health

250 th sides of the active site as inhibitors of dengue virus protease.

251 tidic inhibitors of the Zika, West Nile, and dengue virus proteases.

252 Among a panel of 18 dengue virus-reactive human monoclonal antibodies, four

253 th P bodies in uninfected cells and with the dengue virus replication complex after infection.

254 of Wolbachia on cholesterol homeostasis and dengue virus replication in Aedes aegypti.

255 virus control and it has been suggested that dengue virus replication is regulated by Dnmt2-mediated

256 ion (UTR), is critical for the initiation of dengue virus replication, but quantitative analysis of t

257 igated whether Zika virus antibodies enhance dengue virus replication, by exposing C57Bl/6 mice to Zi

258 nterferon-stimulated gene IRAV (FLJ11286) on dengue virus replication.

259 2 challenged with E.cloacae or infected with Dengue virus revealed high transcripts levels of genes a

260 onstrate specificity against closely related Dengue virus sequences.

261 Using a dengue virus serotype 2 (DENV-2) vaccine strain (PDK53),

262 Zika virus and dengue virus serotype 2 were isolated from a patient wit

263 omplex with the envelope glycoprotein E from dengue virus serotype 2, revealing that the recognition

264 The dengue virus serotype 3 NS4B was reconstituted into lyso

265 Here we map a region on dengue virus serotype 3 recognized by the human neutrali

266 We performed a fragment screen on the dengue virus serotype 3 RNA-dependent RNA polymerase usi

267 s of the DENV3-specific 5J7 mAb epitope into dengue virus serotype 4 (DENV4).

268 rs and recipients, we assess the dynamics of dengue virus serotype 4 during the 2012 outbreak in Rio

269 operties of human antibodies that neutralize dengue virus serotype 4.

270 Dengue virus envelope protein from all four Dengue virus serotypes (DEN-80E) formulated with ionizab

271 Dengue, caused by four dengue virus serotypes (DENV-1 to DENV-4), is a highly p

272 The 4 dengue virus serotypes (DENV-1-4) cause the most prevale

273 that is safe and effective against all four dengue virus serotypes (DENV-1-4) in recipients of all a

274 Infection with any of the 4 related dengue virus serotypes (DENV-1-4) is thought to result i

275 incidence of infection with any of the four dengue virus serotypes (DENV1 to -4) has increased drama

276 The four dengue virus serotypes (DENV1-4) are mosquito-borne flav

277 es on the envelope (E) protein of viruses of dengue virus serotypes 1, 2, and 3 targeted by human neu

278 both efficient mosquito vectors and the four dengue virus serotypes between population centers.

279 Dengue is caused by any of the four related dengue virus serotypes DEN-1, -2, -3 and -4, which are t

280 rm protective efficacy against each of the 4 dengue virus serotypes remains to be definitively determ

281 Infection with any of the 4 dengue virus serotypes results in a diverse range of sym

282 There are four closely related dengue virus serotypes.

283 vaccine design, as an ideal vaccine against dengue virus should efficiently protect against all sero

284 study, we address the protective capacity of dengue virus-specific antibodies that are produced by pl

285 During a repeat infection, dengue virus-specific immune memory cells are reactivate

286 Despite antigenic similarities with dengue viruses, structural studies have suggested the ex

287 iple species, reveal a promising tetravalent Dengue virus sub-unit vaccine candidate.

288 verified for strong Zika virus-neutralizing, dengue virus-subneutralizing capacity.

289 thus far that causes disease in humans, from dengue virus to ZIKV, antagonizes the host type I interf

290 tes the technical feasibility of engineering dengue viruses to display targets of protective antibodi

291 the epidemic to an epidemiological model of dengue virus transmission based on climate and mobility

292 ctions is expected to translate into reduced dengue virus transmission if sufficient individuals are

293 ividuals are thought to play a major role in dengue virus transmission.

294 es against HIV1-p17, hemagglutinin (HA), and dengue virus type I.

295 his immune correlate may be a key target for dengue virus vaccine development.

296 t serotypes, the development of a successful Dengue virus vaccine has proven to be challenging.

297 es aegypti, the latter an important Zika and Dengue virus vector insensitive to Ls Bin.

298 ections by many different viruses, including dengue virus, West Nile virus, Ebola virus, Marburg viru

299 tes in double-membrane vesicles, but not for dengue virus, which replicates via a distinct membrane c

300 Dengue viruses, which infect millions of people per year